Insights - QLT Inc (QLTI) reported positive retreatment data on Thursday for its synthetic oral retinoid compound QLT091001 (-001), indicated for the orphan designated Leber Congenital Amaurosis … Continue Reading
Read NowInsights - Our timing couldn't have been much worse this week, though our thesis is intact on this nutraceutical business.
Premium: Read NowInsights - Bristol-Myers Squibb (BMY) on Monday announced that the U.S. FDA granted its investigational DCV Dual Regimen (daclatasvir and asunaprevir) Breakthrough Therapy Designation as a combination therapy … Continue Reading
Read NowInsights - Arrowhead Research (ARWR), which develops targeted RNAi therapeutics, pulled down gross proceeds of $104 million on Wednesday through the sale of its common stock, a … Continue Reading
Read NowInsights - XenoPort (XNPT) provided an update to investors in mid-January that shed light on possible approval pathways for clinical stage assets while also commenting on progress … Continue Reading
Read NowInsights - It looks like a risk associated with some approved antibiotics may not be a concern for Cempra’s (CEMP) own late-stage candidate, solithromycin. Cempra announced on … Continue Reading
Read NowInsights - Two weeks ago with the release of data from an ongoing phase 2 study of the company’s oncology candidate, PSMA ADC, shares of Progenics Pharmaceuticals (PGNX) took … Continue Reading
Premium: Read Now
